Advanced searches left 3/3
Search only database of 8 mil and more summaries

Plymouth Healthcare Products Llc

Summarized by PlexPage
Last Updated: 02 July 2021

* If you want to update the article please login/register

General | Latest Info

Bmp Sunstone Corporation, through its subsidiaries, manufactures, markets, and distributes over-counter pharmaceutical products for women and children in China. It operates in three segments: manufacture products, Pharmaceutical Distribution, and licensed products. The Manufactured Products segment offers Goodbaby brand family that includes Pediatric Paracetamol and Amantadine Hydrochloride granules, Pediatric Huatan coughing granules, Pediatric Kechuanling oral solution, Amoxicillin and Clavulanate dispersible tablets for children, Amoxicillin dispersible tablets, Roxithromycin dispersible tablets, Pidotimod tablets, Montmorillonite granules, and Pediatric vitamin granules; Confort brand that includes multiple Products for vaginal infections; and Nemei brand family that consist of various OTC women s Health Products relate to nutrition and general well being. The Pharmaceutical Distribution segment distributes traditional Chinese medicines, chemical pharmaceutical preparations, chemical pharmaceutical products, antibiotics, biochemical drugs, biological products, and psychotropic drugs, raw materials for medicinal precursor chemicals, Category II psychotropic drugs, and peptide hormones. The License Products segment focuses on obstetrics, gynecology, and pediatrics; and provides a package of tailored market-entry services from registration of imported medicines through professional promotion of approved products and life-cycle management for western pharmaceutical manufacturers that are seeking to enter the Chinese market. It has strategic alliances with China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Company was formerly known as Beijing Med-Pharm Corporation and changed its name to BMP Sunstone Corporation in February 2008. Company was incorporated in 2003 and is based in Plymouth Meeting, Pennsylvania. As of February 24, 2011, BMP Sunstone Corporation operates as a subsidiary of Sanofi. Stantec Inc. Is an international professional services company in the design and consulting industry. Found in 1954, as D. R. Stanley Associates in Edmonton, Alberta. Stantec provides professional consulting services in planning, engineering, architecture, interior design, landscape architecture, surveying, environmental sciences, project management, and project economics for infrastructure and facilities projects. The company provides services on projects around the world through over 22 000 employees operating out of more than 400 locations in North America and 7 locations internationally. Ims Health is an American company that provides information, services and technology for the healthcare industry. It is the largest vendor of US physician prescribing data. Ims Health was founded in 1954 by Bill Frohlich and David Dubow. In 2010, IMS Health was taken private by TPG Capital, CPP Investment Board and Leonard Green & Partners. Companies go public on April 4 2014 and begin trading on the NYSE under the symbol IMS. Ari Bousbib is IMS Health's Chairman and CEO. Bousbib, formerly a longtime senior executive at United Technologies Corporation, joined the company in September 2010. Ims Health is headquarters in Danbury, Connecticut. Ims Health incorporate is information and technology services company catering to the healthcare industry. Companies collect, maintains, standardize, organize, structures, and integrate healthcare information including sales, prescription and promotional data, medical claims, electronic medical records, and social media. It offers IMS One, cloud application that enables clients to perform business analytics of healthcare data on diseases, treatments, costs and outcomes.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Hypersensitivity

Nickel desensitization schedule:

WeekAmount of Time to Take Medication Prior to Breakfast
Week 11 tablet With Breakfast
Week 21 tablet 15 min Prior
Week 31 tablet 30 min Prior
Week 41 tablet 45 min Prior
Week 51 tablet 1 hour Prior
Week 6 and thereon2 tablets 1 hour Prior

Plymouth MEETING, PA. And CHICAGO, Oct. 14 2020 / PRNewswire /-HARMONY Biosciences Holdings, Inc., Pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced the US Food and Drug Administration has approved WAKIX for treatment of cataplexy in adult patients with Narcolepsy. Wakix is the first and only treatment approved by FDA for people with excessive daytime sleepiness or cataplexy associated with Narcolepsy that is not scheduled as a control substance by the US Drug Enforcement Administration. Wakix received FDA approval for treatment of excessive daytime sleepiness in adult patients with Narcolepsy in August 2019. All people living with Narcolepsy have excessive daytime sleepiness and up to two-thirds of them also experience cataplexy, which is one of the most debilitating symptoms of this chronic, rare neurological disorder, said Harmonys Chief Medical Officer, Jeffrey Dayno, MD Today FDA approval of cataplexy indication for WAKIX, coupled with it being first and only non-schedule treatment option approve for adult patients with Narcolepsy to treat both excessive daytime sleepiness or cataplexy, provide opportunity for WAKIX to offer broad clinical utility to healthcare professionals managing adult patients living with Narcolepsy. This approval underscores our ongoing commitment to supporting people who are living with Narcolepsy, said John C. Jacobs, Harmonys President and Chief Executive Officer. At HARMONY, we always keep patients at the heart of all we do and with this approval, we are inspired to continue our mission to develop novel treatment options for those living with rare, neurological disorders who have unmet medical needs. From the very beginning, our passion at Bioprojet has been to bring WAKIX to people living with daily challenges that are associated with impaired wakefulness and risk of cataplexy attacks. This approval highlights recognition by FDA of a new therapeutic option for treatment of two major symptoms of Narcolepsy by drug with a novel mechanism of action, said Professor Jean-Charles Schwartz, PhD. Professor Schwartz is a discoverer of histaminergic neurotransmission in the brain and histamine-3 receptor, which is the target receptor of WAKIX. He is also co-founder, with Jeanne-Marie Lecomte, of Bioprojet. Wakix, first-In-class medication, is a selective histamine 3 receptor antagonist / inverse agonist that works through a novel mechanism of action to increase synthesis and release of histamine, wake-promoting neurotransmitter in the brain. Wakix is administered orally, once daily in the morning upon wakening. Fda approval of WAKIX for treatment of cataplexy in adult patients with Narcolepsy is based on results from two randomized, control trials from the clinical development program for WAKIX. After complete response letter for cataplexy indication was issued by FDA in August 2019, HARMONY met with the Agency in December 2019 to discuss deficiencies cited in CRL.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Carcinogenesis, mutagenesis, impairment of fertility

Table

WeightStarting DoseMax. Dose
50-100 lbstablet1 tablet
100-150 lbs1 tablet2 tablets
150-200 lbs2 tablets4 tablets
over 200 lbs3 tablets6 tablets

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Sources

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

logo

Plex.page is an Online Knowledge, where all the summaries are written by a machine. We aim to collect all the knowledge the World Wide Web has to offer.

Partners:
Nvidia inception logo

© All rights reserved
2021 made by Algoritmi Vision Inc.

If you believe that any of the summaries on our website lead to misinformation, don't hesitate to contact us. We will immediately review it and remove the summaries if necessary.

If your domain is listed as one of the sources on any summary, you can consider participating in the "Online Knowledge" program, if you want to proceed, please follow these instructions to apply.
However, if you still want us to remove all links leading to your domain from Plex.page and never use your website as a source, please follow these instructions.